• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 POS filed by NuCana plc

    7/16/25 9:27:29 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    F-6 POS 1 e664698_f6pos-nucana.htm

     

    As filed with  the Securities and Exchange Commission on July 16, 2025 Registration No. 333-286737 

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     __________________________________

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

    AMERICAN DEPOSITARY RECEIPTS

     _____________

     

    NUCANA PLC

    (Exact name of issuer of deposited securities as specified in its charter)

     _____________

     

    N/A

    (Translation of issuer’s name into English)

     _____________

     

    England and Wales

    (Jurisdiction of incorporation or organization of issuer)

     __________________________________

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

     _____________

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248-4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

     _____________

     

    Corporation Service Company

    251 Little Falls Drive, Wilmington, DE 19808

    United States

    (302) 421-6100

    (Address, including zip code, and telephone number, including area code, of agent for service)

     __________________________________

     

    Copies to:

     

    William C. Hicks, Esq.

    John T. Rudy, Esq.

    Allyson Wilkinson, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky

    and Popeo, P.C.

    One Financial Center

    Boston, Massachusetts 02111

    (617) 542-6000

     

    Herman H. Raspé, Esq.

    Jean-Claude Lanza, Esq.

    Patterson Belknap Webb & Tyler LLP
    1133 Avenue of the Americas
    New York, New York 10036
    (212) 336-2000

      

    It is proposed that this filing become effective under Rule 466: ☐  immediately upon filing.
      ☐  on (Date) at (Time).
    If a separate registration statement has been filed to register the deposited shares, check the following box : ☐

     __________________________________

     

    CALCULATION OF REGISTRATION FEE

     

    Title of Each Class of
    Securities to be Registered
    Amount to be
    Registered

    Proposed Maximum

    Aggregate Price Per Unit*

    Proposed Maximum

    Aggregate Offering Price**

    Amount of

    Registration Fee

    American Depositary Shares (the “ADS(s))”, each ADS representing the right to receive five thousand (5,000) ordinary shares of NuCana plc (the “Company”) N/A N/A N/A N/A

     

    * Each unit represents 100 ADSs.
    ** Estimated solely for the purpose of calculating the registration fee.  Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.
       
       
      The Registrant hereby amends this Post-Effective Amendment No. 1 to Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Post- Effective Amendment No. 1 to Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Post- Effective Amendment No. 1 to Registration Statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

    This Post-Effective Amendment No. 1 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

     

    ii

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

     

     

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

             
    1. Name of Depositary and address of its principal executive office   Face of Receipt - Introductory Article.
             
    2. Title of Receipts and identity of deposited securities   Face of Receipt - Top Center.
             
    Terms of Deposit:    
             
      (i) The amount of deposited securities represented by one American Depositary Share ("ADSs")   Face of Receipt - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt - Paragraphs (17)
    and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt - Paragraph (14);
    Reverse of Receipt - Paragraph (18).
             
      (v) The sale or exercise of rights  

    Reverse of Receipt - Paragraphs (15)

    and (17).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (3) and (6);

    Reverse of Receipt - Paragraphs (15) and (17).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).

     

    I-1 

     

     

     

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

             
      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt - Paragraphs (2), (3), (4), (6), (7), (9) and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

    3.     Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2. AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

     

    The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

     

    I-2 

     

     

    PROSPECTUS

     

    The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amendment No. 1 to the Amended and Restated Deposit Agreement filed as Exhibit (a)(i) to this Post-Effective Amendment No. 1 to the Registration Statement on Form F-6 and is incorporated herein by reference.

     

    I-3 

     

      

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)(i) Form of Amendment No. 1 to Amended and Restated Deposit Agreement, by and among NuCana plc (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(i).
       
      (ii) Amended and Restated Deposit Agreement, dated as of May 7, 2025, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”) ___ Filed herewith as Exhibit (a)(ii).

     

    (b)(i) At-the-Market Program Letter Agreement, dated as of April 6, 2020, by and between the Company and the Depositary. ___ Previously filed as Exhibit (b)(i) to the Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, Reg. No. 333-220392, filed on March 27, 2024, and incorporated herein by reference.
       
      (ii) Restricted ADS Letter Agreement, dated as of July 31, 2018, by and between the Company and the Depositary. ___ Previously filed as Exhibit (b)(ii) to the Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, Reg. No. 333-220392, filed on March 27, 2024, and incorporated herein by reference.

      

    (c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Previously filed as Exhibit (d) to Registration Statement on Form F-6 (Reg. No. 333-286737) with the Commission on April 24, 2025 and incorporated herein by reference.

     

    (e)Certificate under Rule 466. ___ None.

     

    (f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

     

    II-1 

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

     

    II-2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Amended and Restated Deposit Agreement, by and among NuCana plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 16th day of July, 2025.

     

      Legal entity created by the Amended and Restated Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive five thousand (5,000) ordinary shares of NuCana plc.
       
      CITIBANK, N.A., solely in its capacity as Depositary
         
      By:   /s/ Thomas Crane
        Name:  Thomas Crane
        Title:    Vice President

     

    II-3 

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, NuCana plc certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Nether Alderley, United Kingdom, on July 16, 2025.

     

      NUCANA PLC
         
      By:  /s/ Andrew Kay
        Name:  Andrew Kay
        Title:    Executive Chairman of the Board of Directors and Acting Principal Executive Officer

     

    II-4 

     

      

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 has been signed by the following persons in the following capacities on July 16, 2025.

     

    Signature   Title
         
    /s/ Andrew Kay   Executive Chairman of the Board of Directors and Acting Principal
    Andrew Kay   Executive Officer (Principal Executive Officer) and Director
         
    /s/ Ian Webster   Interim Chief Financial Officer (Principal Financial and
    Ian Webster   Accounting Officer)
         
    /s/ Cyrille Leperlier   Director
    Cyrille Leperlier    
         
    /s/ Martin Mellish   Director
    Martin Mellish    
         
    /s/ Elliott Levy   Director
    Elliott Levy    

     

    II-5 

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT

     

    Under the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this Post-Effective Amendment No. 1 to Registration Statement on Form F-6 in Spring Branch, Texas, on July 16, 2025.

     

      NUCANA, INC.
         
      By: /s/ Jeffrey D. Bloss
      Name:   Jeffrey D. Bloss
      Title:     Chief Medical Officer

     

    II-6 

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page

         
    (a)(i) Form of Amendment No. 1 to Amended and Restated Deposit Agreement  
         
    (a)(ii) Amended and Restated Deposit Agreement  

     

    II-7

     

    Get the next $NCNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    SEC Filings

    View All

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/20/25 4:20:04 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/1/25 4:22:05 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    7/21/25 8:15:16 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

    First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development pr

    8/20/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Announces ADS Ratio Change

    EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces that it will implement the Company's previously disclosed plans to change the ratio of its American Depository Shares ("ADSs") to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Effective Date").   For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-two hundred reverse ADS split and will have no impact on an ADS holder's pro

    8/1/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

    EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company's June 27, 2025 announcement of the agreements to cancel the remaining Series A Warrants, 59.5 million as at June 26, 2025, in exchange for a payment of $3.6 million. This initiative fully eliminates all overhanging rights from the regis

    7/21/25 8:05:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care